First Exchange: Laying the Foundation for Cooperation and Jointly Mapping Out the Development Blueprint (November 26, 2024)
On November 26, 2024, Lin Hong, General Manager of China National Pharmaceutical Machinery (Shanghai) Corporation, visited Sinboda’s headquarters. She was received by Dr. Xiaohua Chen, CEO of Sinboda, Dr. Bing Li, CTO, and Gui Jian, Deputy General Manager. Dr. Chen systematically presented the company’s development history, technology foundation, and original achievements, and accompanied the delegation on a tour of the R&D laboratories, highlighting the progress of core product development and validation data. The two parties conducted pragmatic discussions on industry trends, application scenarios, and channel cooperation models.
During the subsequent symposium and preliminary signing ceremony, Shi Zhenxing, Secretary of the Party Working Committee of Wutong Street, attended and delivered remarks on behalf of the local government: Tongxiang City is accelerating the development of future industries, with life sciences and medical devices as key focus areas, and a dedicated industrial park is already under construction. Secretary Shi noted that Sinboda has grown rapidly since its establishment and is a key enterprise receiving focused attention and support. He expressed the expectation that Sinboda would serve as a bridge, leveraging the effect of “attracting talent through talent, and attracting enterprises through enterprises,” to draw more high-quality companies to settle in Tongxiang and jointly build an industrial ecosystem. He also expressed hope for deeper cooperation with China National Pharmaceutical Machinery (Shanghai) Corporation in the future, promoting strategic synergy and channel collaboration upgrades with the local industrial cluster, advancing toward “Tongxiang Investment Promotion 2.0.”
From the strategic perspective of a central state-owned enterprise (SOE), General Manager Lin Hong emphasized: SOEs place great importance on coordination with local governments and are willing to join hands with Tongxiang to inject momentum into industrial upgrading and corporate development. This visit not only completed an on-site assessment of Sinboda and established preliminary cooperation intentions but also facilitated in-depth exchanges with the local government on the industrial development blueprint, laying a solid foundation for subsequent government-enterprise collaboration.
During this engagement, China National Pharmaceutical Machinery (Shanghai) Corporation conducted a systematic evaluation of Sinboda’s technology and products, and both parties reached a preliminary intention for comprehensive channel cooperation. China National Pharmaceutical Machinery (Shanghai) Corporation highly recognized Sinboda’s global product capabilities and innovation capacity, and expressed full confidence in future cooperation.
Second Exchange: Deepening Product Understanding and Driving Cooperation Implementation (April 18, 2025 – August 6, 2025)
On April 18, 2025, Dr. Xiaohua Chen, CEO of Sinboda, led the marketing team to visit China National Pharmaceutical Machinery (Shanghai) Corporation and China Scientific Equipment Co., Ltd. for in-depth discussions on industrial synergy and cooperation opportunities. During the meeting, Dr. Chen delivered a systematic and professional introduction to Sinboda’s product portfolio, core technology platforms, and multi-scenario applications. The two teams engaged in pragmatic discussions on key issues such as collaborative market deployment, channel development mechanisms, and subsequent cooperation pathways, in light of industry trends and their respective resource endowments.
Over the following four months, China National Pharmaceutical Machinery (Shanghai) Corporation organized systematic market research and multi-dimensional evaluation of Sinboda’s products, visiting benchmark users including the Model Animal Center of Tsinghua University, the National Institutes for Food and Drug Control (NIFDC), and the Capital Medical University system, while also coordinating with distributors across Hebei, Beijing, and Northeast China to verify frontline demand and user feedback. The extensive and in-depth field research fully confirmed the broad scenario-based demand and technological leadership of Sinboda’s products.
On this basis, the two parties reached agreement on procurement cooperation on August 6, 2025, and signed a purchase order of RMB 21 million; the first batch of 9 units of the ScimaX AI (AI-Controlled Single Cell In-suit Manipulator) has been successfully shipped, marking the transition from the intention phase to full substantive implementation.
Third Exchange: Deepening Product Understanding and Driving Cooperation Implementation (August 27, 2025)
On August 27, 2025, Lin Hong, General Manager of China National Pharmaceutical Machinery (Shanghai) Corporation, led her core team to visit Sinboda. Building upon the existing purchase order of RMB 21 million, the two parties further clarified the direction for cooperation upgrades, embarking on a new journey of win-win outcomes. The visiting team toured the exhibition hall, R&D center, and production workshop, gaining systematic insights into the full-process system from original R&D and large-scale manufacturing to quality control.
During the subsequent symposium, the two parties held in-depth discussions on business advancement following the cooperation implementation, near-term sales targets, and mid-to-long-term collaborative pathways. Dr. Zhang Kunming, Marketing Director of Sinboda, systematically presented the technical features and application scenarios of the core products, detailing target customers and market segments, and outlining current actionable cooperation opportunities. The sales teams from both sides engaged in pragmatic exchanges on customer development mechanisms, channel synergy, regional coverage, and other topics.
General Manager Lin Hong of China National Pharmaceutical Machinery (Shanghai) Corporation stated that this cooperation marks the company’s first deep collaboration with a domestic high-value scientific instrument enterprise. Introducing Sinboda’s high-end “Intelligent Manufacturing in China” equipment, which boasts global innovation and international competitiveness, represents an important strategic move for China National Pharmaceutical Machinery (Shanghai) Corporation in the relevant field. Joining hands with Sinboda signifies a new phase of coordinated development between central SOEs and private enterprises. Both parties will jointly advance the marketization of globally original equipment, enhance the international influence of “China Solutions,” and leverage China’s advanced productive forces to compete in and help shape the global life science equipment landscape, thereby contributing to the industry’s high-quality development.
Dr. Xiaohua Chen, CEO of Sinboda, shared the company’s market expansion plans and new product development strategies during the meeting, and expressed sincere gratitude to China National Pharmaceutical Machinery (Shanghai) Corporation for choosing to sign the cooperation agreement at the early stage of product launch. She noted that partnering with a “national team” channel player with strong capabilities and brand influence in the scientific instrument field is both an honor and a responsibility. This signing is merely the starting point; in the future, both parties will continue to deepen collaboration, expand application scenarios, and strengthen the industrial ecosystem. Sinboda will remain committed to being technology-driven and product-leading, accelerating its journey toward becoming a global leader in engineering-based life sciences, driving the deep integration of AI and life sciences, and creating an even more internationally competitive “China Solution.”
